Impact of G-CSF utilization on the incidence of neutropenia and total cost of care between patients receiving first line nab-Paclitaxel plus gemcitabine or FOLFIRINOX for metastatic pancreatic cancer
Author(s)
Parisi M1, Patel M1, Belk K2, Craver CW3
1Celgene Corporation, Summit, NJ, USA, 2MedAssets, Mooresville, NC, USA, 3MedAssets, Inc., Huntersville, NC, USA
OBJECTIVES: The purpose of this study is to examine the incidence of neutropenia and use of prophylactic granulocyte-colony stimulating factor (G-CSF) between nab-Paclitaxel plus gemicitabine (nab-P+G) and FOLFIRINOX (FFX) as first-line treatment for metastatic pancreatic cancer (mPAC). METHODS: A retrospective cohort study was conducted using de-identified hospital (inpatient and outpatient) administrative data from MedAssests. Patients (≥18 yo) diagnosed with mPAC between Apr 2013 and Feb 2015, completing ≥ 1 cycle of first-line therapy with either nab-P+G or FFX, and with ≥ 6 months of data were included. Treated patients and G-CSF utilization were identified using hospital charge records and incidence of neutropenia was identified using diagnosis codes. Between group differences were tested using Chi-Square (Fisher’s exact for low volume) and multivariable logistic regression. RESULTS:
Conference/Value in Health Info
2016-05, ISPOR 2016, Washington DC, USA
Value in Health, Vol. 19, No. 3 (May 2016)
Code
PCN43
Topic
Epidemiology & Public Health
Disease
Oncology